

# Design of the pilot, proof of concept REMOTE-COVID trial: REmote MOniToring usE in suspected cases of COVID-19 (SARS-CoV 2)

## A trial protocol

Fahad Mujtaba Iqbal<sup>1\*</sup>, Meera Joshi<sup>1</sup>, Gary Davies<sup>2</sup>, Sadia Khan<sup>2</sup>, Hutan Ashrafian<sup>1</sup>, Ara Darzi<sup>1</sup>

- 1) Division of Surgery & Cancer, 10<sup>th</sup> Floor Queen Elizabeth the Queen Mother Wing (QEQM) St Mary's Campus, London, W2 1NY
- 2) West Middlesex University Hospital, Twickenham Road, Isleworth, TW7 6AF

Clinical trials registration information: ClinicalTrials.gov Identifier: NCT04337489

16 March 2020

16 Abstract:

17 Background: The outbreak of SARS-CoV-2 (coronavirus, COVID-19), declared a pandemic by the  
18 World Health Organisation (WHO) is global health problem with ever-increasing attributed deaths.  
19 Vital sign trends are routinely used to monitor patients with changes in these parameters often  
20 preceding an adverse event. Wearable sensors can measure vital signs continuously (e.g. heart rate,  
21 respiratory rate, temperature) remotely and can be utilised to recognise early clinical deterioration.

22 Methods: We describe the protocol for a pilot, proof-of-concept, observational study to be  
23 conducted in an engineered hotel near London airports, United Kingdom. The study is set to  
24 continue for the duration of the pandemic. Individuals arriving to London with mild symptoms  
25 suggestive of COVID-19 or returning from high risk areas requiring quarantine, as recommended by  
26 Public Health England, or healthcare professionals with symptoms suggestive of COVID-19 unable to  
27 isolate at home will be eligible for a wearable patch to be applied for the duration of their stay.  
28 Notifications will be generated should deterioration be detected through the sensor and displayed  
29 on a central monitoring hub viewed by nursing staff, allowing for trend deterioration to be noted.  
30 The primary objective is to determine the feasibility of remote monitoring systems in detecting  
31 clinical deterioration for quarantined individuals in a hotel.

32 Discussion: This trial should prove the feasibility of a rapidly implemented model of healthcare  
33 delivery through remote monitoring during a global pandemic at a hotel, acting as an extension to a  
34 healthcare trust. Potential benefits would include reducing infection risk of COVID-19 to healthcare  
35 staff, with earlier recognition of clinical deterioration through ambulatory, continuous, remote  
36 monitoring using a discrete wearable sensor. We hope our results can power future, robust future  
37 randomised trials.

38 Trial registration: ClinicalTrials.gov Identifier: NCT04337489

39 Keywords: remote sensing technology; protocol; clinical trial; patient deterioration; monitoring,  
40 ambulatory.

41 Background:  
42 The recent outbreak of SARS-CoV-2 (COVID-19), declared a pandemic by the World Health  
43 Organisation (WHO) and a growing global health problem, has stretched resources, creating  
44 pressures within the National Health Service (NHS) with implications for patient safety.<sup>1</sup> UK Chief  
45 Medical Officers have raised the risk to the UK to high, with ever increasing confirmed cases and  
46 attributed deaths.<sup>1</sup>

47 High risk travellers with suspected or confirmed cases of COVID-19 are likely to transferred  
48 immediately to hospital. However, travellers with milder symptoms or returning from high risk  
49 areas, a two-week period of observation/quarantine may be required, in accordance with Public  
50 Health England recommendations.<sup>2</sup> The rate of clinical deterioration for individuals suffering with  
51 COVID-19 remains unknown; given that widespread vaccine deployment remains imminently  
52 unforeseeable, novel strategies are required in approaching this pandemic.

53 Vital signs trends (heart rate, respiratory rate, blood pressure, temperature, oxygen saturations) are  
54 routinely used for monitoring hospital patients.<sup>3</sup> Clinical deterioration may be recognised through  
55 changes in these parameters, and often precedes an adverse event.<sup>4,5</sup> As such, The National  
56 Institute for Health and Care Excellence (NICE) and the Royal College of Physicians (RCP) recommend  
57 that all patients have their vital signs recorded every 12h as a minimum.<sup>6,7</sup>

58 Across the National Health Service (NHS), the use of the National Early Warning Score 2 (NEWS), a  
59 'track and trigger' warning score, has been implemented in accordance with the RCP to guide on  
60 escalation protocols and monitoring frequency of vital signs.<sup>7</sup> Accordingly, heart rate (HR),  
61 respiratory rate (RR), temperature, blood pressure, oxygen saturations, and level of consciousness  
62 are assessed every 4-6 hours with more frequent monitoring for acutely unwell patients.

63 Progression in non-invasive digital technologies have renewed potential for remote monitoring  
64 solutions.<sup>8,9</sup> Wearable sensors offer an opportunity for sensor alerting systems to continuously  
65 monitor vital parameters remotely, recognise early deterioration and support clinical decision

66 making, allowing people to receive monitoring outside of expensive hospital facilities; in resource  
67 limited hospitals; and utilising alternate sites in crisis scenarios.<sup>10</sup>

68 Previous studies have demonstrated acceptability and practicability of continuous monitoring using  
69 wearable sensors on general surgical and medical wards in the UK and The Netherlands.<sup>11,12</sup> Initial  
70 work by Downey et al. were limited by imbalanced randomisation leading to significant baseline  
71 differences across the two trial arms and failure to adjust for these in their analyses.<sup>11</sup> Nevertheless,  
72 the wearable sensor seemed to demonstrate feasibility in hospital settings. Qualitative analyses,  
73 through semi-structured interviews for patients and healthcare staff, similarly favoured continuous  
74 the notion of continuous vital sign monitoring in general wards.<sup>12</sup> It should be noted that many of  
75 the patients interviewed were admitted for malignant disease which is likely to influence qualitative  
76 outcomes. Delivery of healthcare outside of hospital facilities (e.g. in hotels) is theoretically possible  
77 through continuous remote monitoring of vital signs but has yet to be studied; given the global  
78 pandemic and fear of future waves, evaluation of its viability is justified.

79 Here, we describe the design of our pragmatic trial, exploring the feasibility of remote monitoring  
80 systems in suspected cases of COVID-19 at a hotel, primarily as earlier recognition of clinical  
81 deterioration.

82 Methods:

83 *Overall design:*

84 This pragmatically designed, pilot, proof-of-concept, observational study was reviewed and  
85 approved by London – Queen Square Research Ethics Committee (IRAS: 281757) and this protocol  
86 was developed in accordance with recommendations from the Standard Protocol Items:  
87 Recommendations for Interventional Trials (SPIRIT) guidelines.<sup>13</sup> The objective is to determine the  
88 feasibility of remote healthcare delivery in a hotel with rapid implementation in the COVID-19 era.  
89 Feasibility will be tested through rate of participation and number of vital alerts generated.

90 The SensiumVitals™ (Sensium Healthcare Ltd., United Kingdom) system can be engineered in the  
91 building (hotel) for use with the wearable sensor. All participants would be fitted with the sensor on  
92 arrival and would always be worn. A designated area within the facility would act as a central hub  
93 allowing for remote monitoring to occur by healthcare staff. Alerts would be generated, in  
94 accordance with NEWS parameters (Table 1) but can be individually tailored, to identify  
95 deteriorating participants. Participants can be escalated to hospitals should rapid deteriorating in  
96 vital signs be noted; ambulance services and paramedics will be present on site to facilitate this. The  
97 decision to escalate will come from a senior nurse, present on site, or a general practitioner  
98 contactable at all times.. The temperature alert threshold was lowered to the lowest score in the  
99 NEWS chart, allowing for earlier detection and improved sensitivity<sup>14</sup>; this decision was made from  
100 previous work which demonstrated varying limits of agreement for temperature when compared to  
101 nursing observations.<sup>15</sup> Escalation protocols will be developed and trialled, allowing staff to address  
102 issues as they arise (Figure 1).

103 *Wearable sensor system*  
104 SensiumVitals™ by the Surgical Company, have produced a lightweight, waterproof, single-use,  
105 wearable wireless ‘patch’ with a battery life of 5 days measuring vital signs every two minutes. The  
106 sensor attaches to an individual’s chest with two ECG electrodes, recording HR, RR, and a wire  
107 attaches around the individual’s back, measuring axillary temperature. The sensor is FDA approved  
108 and CE marked. Data are transmitted through radiofrequency and dedicated intranet hotspots.  
109 Physiological parameters can be viewed by clinical staff on a mobile device/desktop computer,  
110 allowing trends towards deterioration to be noted, with tailored alerts generated for deteriorating  
111 individuals in accordance with NEWS (Figure 2).

112 All sensor data collected by the SensiumVitals® system will be stored on a created secured hotel  
113 network; access to which is restricted to research personnel. Given that the hotel acts as an

114 extension to a healthcare trust, the SensiumVitals® system inherits all the hospital procedures and  
115 data backup policies, ensuring data access and servers are secured.

116 In line with the principles of Good Clinical Practice guidelines, data will be securely archived for a  
117 minimum of 5 years.

118 Following the completion of quarantine, participants will be invited to share their experiences  
119 through using semi-structured interviews and questionnaires. Individual interviews allow for  
120 anonymity and truthful perceptions/attitudes. This method enables narratives to be elicited through  
121 guided but open questioning.

122 *Hypotheses:*

123 1) Continuous remote monitoring with wearable sensors of vital signs will identify  
124 deteriorating patients.  
125 2) Healthcare provision in a hotel will be feasible and acceptable amongst healthcare staff  
126 and participants.

127 *Sequence of events:*

128 Patching patients and using data for academic research

129 1. Eligible participants from the airport will be transferred to the hotel by paramedics.  
130 2. Upon arrival to the engineered hotel, an initial assessment of all participants will be  
131 undertaken. A study information sheet will be provided, and informed consent taken for  
132 wearable sensors to be applied, allowing remote monitoring of vital signs. To ensure  
133 appropriate quarantine.  
134 3. In a designated area within the building, a central monitoring hub will be set up to monitor  
135 the recorded parameters by National Health Service (NHS) healthcare staff from a local  
136 Trust. The hub contains a site manager, porters, security staff, nurses, ambulance services,  
137 professional cleaners, and hotel staff.

138 4. If a participant deteriorates, an alert should be generated on a smartphone device/desktop  
139 computer; following this, an escalation protocol will be trialled to action the alert in an  
140 appropriate manner; hospitalisation may be necessary. Initially, nursing staff will gather  
141 more information through telephone review. Following this, a virtual GP can be contacted  
142 for further advice. Ambulance services and paramedics will be on-site to facilitate  
143 hospitalisation should rapid deterioration occur. These healthcare professionals are  
144 independent and can provide oversight.

145 5. Participants will be invited for an interview and be asked to complete a survey on their  
146 experiences following quarantine completion.

147 6. Participant care records will be stored on an online Care Information Exchange system  
148 (compliant with General Data Protection Regulation) that is currently in place across the  
149 trust. Electronic health records and patient notes will be reviewed to determine clinically  
150 relevant events if transfer to hospital occurs (e.g. hospital length of stay, mortality,  
151 escalation to ITU).

152 7. Sensor data will be extracted from the central servers containing sensor data for appropriate  
153 statistical analyses for associated clinical efficacy of health outcomes in COVID-19.

154

155 Semi-structured interviews/Questionnaires (mixed methods)

156 1. All participants alongside healthcare staff will be invited to take part in semi-structured  
157 interviews and be given questionnaires. These will take place by the primary lead researcher  
158 using prepared topic guides.

159 2. Written consent will be obtained from those who agree to participate.

160 3. An audio recording will be made of the interviews. Notes reflecting verbal responses may be  
161 taken. The interviews will be conducted at the engineered hotel.

162 4. The recordings will be transcribed, and the data will undergo thematic analyses.

5. Validated and unvalidated questionnaires will also be given enquiring about experiences (e.g. PHQ-9<sup>16</sup>, GAD-7<sup>17</sup>, satisfaction, anxiety related to the devices).

165

## 166 *Outcomes and progression criteria:*

## 167 Feasibility outcomes:

1. Rate of participation  
Using the confidence interval approach<sup>18</sup>, for a minimum sample size of 10 individuals, we estimate a rate of participation of 90% with a 95% confidence interval of +/- 18%.
2. Generation of an alert following abnormal vital signs (e.g. raised temperature).  
We aim for a minimum of 5 vital alerts to be generated to demonstrate feasibility.
3. Missing data recorded from sensor limited to less than 20% attrition will be a criterion for progression.
4. Number of adverse events relating to the sensor system (e.g., skin reaction to sensor preventing trial continuation)

178 Exploratory clinical outcomes:

1. Actions following alert generation (e.g., phone consultation, virtual general practitioner review, transfer to hospital).
2. Acceptability and usability of the SensiumVitals™ system by healthcare staff and participants (mixed methods analysis)

## 184 *Participant eligibility:*

185 The study will recruit flight arrivals returning to the UK in London. High risk travellers are screened  
186 at the airport and tested for COVID-19, with transfer to hospital if appropriate; this cohort would be  
187 ineligible for the study.

188 Additionally, healthcare professionals who display symptoms of COVID-19 and are unable to isolate  
189 safely at home (e.g. lodging with vulnerable persons) would be eligible to take part in the study and  
190 invited to stay at the hotel.

## 191 Inclusion Criteria

192 • Aged 18 years or over.

- Able to provide written consent.
- Travellers returning with milder symptoms suggestive of COVID-19 or returning from high risk areas requiring quarantine, as recommended by Public Health England.
- Healthcare professionals with milder symptoms suggestive of COVID-19 unable to isolate at home.

## 198 Exclusion Criteria

- Any participants that withdraw their consent.
- A skin condition/reaction preventing wearing the wearable sensor (these can be communicated by the participant to the researcher or healthcare staff at the hotel).
- The presence of a permanent pacemaker or cardiac defibrillator.
- Any form of psychiatric disorder or a condition that, in the opinion of the investigator, may hinder communication with the research team.
- Inability to cooperate or communicate with the research team.

209 Descriptive statistics will be obtained about the baseline characteristics of participants. Continuous  
210 variables will be presented as mean  $\pm$  standard deviation or medians and ranges, depending on  
211 distribution. Categorical variables will be reported as numbers and percentages. The total  
212 frequencies of alerts, proportion of actioned alerts, and resultant actions will be described.  
213 Outcome measures (e.g. phone consultation, virtual GP review, transfer to hospital) will be reviewed  
214 from case notes should escalation occur and described in absolute frequencies. Questionnaire data  
215 will be presented using frequency distributions. Data will be analysed using SPSS, Stata, and  
216 GraphPad.

217 Qualitative analyses:

218 Semi structured interviews will take place by the primary lead researcher using the prepared topic  
219 guides. An audio recording will be made of all interviews. The interviewer may also take field notes  
220 reflecting the verbal responses and reflections to be used to adapt the topic/study direction. The  
221 audio recordings will be transcribed. The data will be analysed appropriately using thematic analysis.

222 To ensure confidentiality and anonymity, each interview will be allocated a pseudonym, to be  
223 applied to the corresponding consent form, topic guide form/field notes and audio file. Their name  
224 will not be included in the audio recording; the pseudonym will be used.

225 Summaries of interview field notes will be typed into a word processor. All paper and soft copies of  
226 field notes, audio files and consent forms will be kept securely in a locker within a locked office and  
227 if in digital format, on a password protected computer and backed up regularly. Information will only  
228 be shared within the study team.

229 Audio recordings will be professionally transcribed verbatim, and a random selection of transcripts  
230 will be checked against recordings for accuracy. Interview transcripts will be analysed using Braun  
231 and Clarke's thematic analysis by two independent researchers; disagreements will be resolved  
232 through discussion.<sup>19</sup> Power considerations:

233 As a pilot study in an unknown viral pandemic, the progression of which is not well established, this  
234 study will appraise the feasibility for hotel remote sensing under these circumstances. Sufficient  
235 other data do not exist to allow for power calculations.

236

237 *Patient and public involvement:*

238 Due to the nature of the pandemic and the current climate (national lockdown advised from the  
239 government) with COVID-19, patient and public involvement was not undertaken for this

240 observational trial. All eligible participants will be approached to enter the study and all recruited  
241 participants can provide email addresses should they wish for dissemination of results.

242 Discussion:

243 To the best of our knowledge, this is the first remote monitoring study focussing on healthcare  
244 delivery during a global pandemic at a remote site (i.e. hotel), acting as an extension to a healthcare  
245 trust. Apart from reducing infection risk to healthcare staff, continuous remote monitoring using a  
246 discrete wearable sensor has the potential to detect earlier clinical deterioration allowing for earlier  
247 intervention and provide further insight into the clinical course of COVID-19 in regards to vital signs.

248 Our pilot study design will test the viability of using a remote site for healthcare delivery during  
249 times of crisis. Continuous vital sign monitoring should provide insight to determine whether vital  
250 sign trends can detect clinical deterioration for COVID-19, requiring hospitalisation. Furthermore,  
251 questionnaires and semi-structured interviews of participants will provide insight into wider  
252 implementation of this technology and provide feedback for improvements. Similarly, semi-  
253 structured interviews of staff will provide a healthcare perspective, particularly thoughts on reducing  
254 potential infection risk through remote monitoring services.

255 Despite the strengths of our study, the design presents inherent limitations. Mainly, the lack of  
256 randomisation and control arm to compare remote monitoring services to 'standard care'.

257 However, to maximise capacity at the hotel given the unknown of the pandemic, a pragmatic,  
258 observational design was favoured; randomisation was not deemed appropriate. Government  
259 restrictions are rapidly changing for air travel, which could significantly alter our sample size,  
260 increasing the risk of type II errors. The inclusion of healthcare professionals may bias the  
261 description of favourable experiences, owing to their familiarity of continuous monitoring of  
262 physiological parameters. In addition, implementing remote monitoring systems entails an initial  
263 financial cost with new logistical and legal considerations; given the early phase of work, the true  
264 extent of these issues remains unknown. If the trial is proven to be feasible, this work could power

265 future randomised trials to explore for cause-effect relationships and describe cost-  
266 utility/effectiveness of remote monitoring solutions.

267 In conclusion, the results of our study would have potential to demonstrate the feasibility of remote  
268 monitoring during a pandemic and may provide insight into earlier recognition of clinical  
269 deterioration in individuals suspected with COVID-19.

270

271 **Declarations**

272 *Ethics approval and consent to participate*

273 All participants must provide consent to participate. This study has been received ethical approval  
274 by London – Queen Square Research Ethics Committee (IRAS: 281757).

275 *Consent for publication*

276 Consent will be taken for publication.

277 *Availability of data and materials*

278 The datasets used and/or analysed during the current study are available from the corresponding  
279 author on reasonable request. Only the authors have access to the dataset.

280 *Competing interests*

281 The authors declare that they have no competing interests

282 *Funding*

283 This work was supported by a grant provided through CW+ (the official charity of Chelsea and  
284 Westminster Hospital). The funding body will play no role in the design of the study and collection,  
285 analysis, and interpretation of data and in writing this manuscript.

286 *Authors' contributions*

287 FMI drafted the manuscript. Amendments were made by MJ, SK, HA, GD, and AD. Statistical  
288 considerations were discussed with MJ, SK and HA. The idea was conceived by MJ and SK.

289 *Acknowledgements*

290 Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research  
291 Centre (BRC) and the NIHR Imperial Patient Safety Translational Research Centre (PSTRC).

292

293 **References:**

- 294 1. Department of Health and Social Care; Public Health England. Coronavirus (COVID-19): latest  
295 information and advice - GOV.UK. <https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public>. Accessed March 6, 2020.
- 297 2. Public Health England. Stay at home: guidance for households with possible coronavirus  
298 (COVID-19) infection - GOV.UK. <https://www.gov.uk/government/publications/covid-19-stay-at-home-guidance/stay-at-home-guidance-for-households-with-possible-coronavirus-covid-19-infection>. Published 2020. Accessed May 6, 2020.
- 301 3. Kenzaka T, Okayama M, Kuroki S, et al. Importance of vital signs to the early diagnosis and  
302 severity of sepsis: association between vital signs and sequential organ failure assessment  
303 score in patients with sepsis. *Intern Med*. 2012;51(8):871-876.
- 304 4. Smith GB. In-hospital cardiac arrest: is it time for an in-hospital 'chain of prevention'?  
305 *Resuscitation*. 2010;81(9):1209-1211.
- 306 5. DeVita MA, Smith GB, Adam SK, et al. "Identifying the hospitalised patient in crisis"—a  
307 consensus conference on the afferent limb of rapid response systems. *Resuscitation*.  
308 2010;81(4):375-382.
- 309 6. National Institutes of Clinical Excellence. *Acutely Ill Patients in Hospital: Recognition of and*

## 346 Figure legends:

347 Figure 1: Potential escalation pathway; NEWS: National Early Warning Score; GP: general

348 practitioner.

349 Figure 2: Monitoring system for SensiumVitals™ Wearable Sensor

350 Table:

351 *Table 1: Criteria for generating vitals alert*

Parameter	Alert threshold
Respiratory rate (breaths per minute)	$\geq 25$
Temperature (Celsius)	$\geq 38.1$
Heart rate (beats per minute)	$\geq 131$

352